Published in Medical Letter on the CDC and FDA, January 1st, 2006
This IND clearance enables Adherex to commence U.S.-based clinical trials of eniluracil, as part of its global development plans.
"This regulatory clearance by the FDA was an important step in our efforts to rapidly develop eniluracil. In less than 4 months, we now have clinical quality drug and have submitted and received regulatory clearance to proceed with our initial clinical trials. We expect these trials...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.